You are here: Home » PTI Stories » National » News
Business Standard

Strides' subsidiary inks pact with SUDA Pharmaceuticals for migraine drug

Press Trust of India  |  New Delhi 

Science Friday said its has entered into an exclusive product development, licensing and supply agreement with Australia's for its novel drug SUD-001H, used in the

Science said this partnership with SUDA is part of its specialty portfolio for the US market.

Under the terms of agreement, SUDA will receive an upfront cash payment of USD 0.4 million and a further payment of USD 0.6 million on reaching certain milestones including the pilot first-in-man clinical study, submission and approval of the product in the US," Science said in a BSE filing.

On commercial sales, SUDA will also receive royalties plus a handling fee.

SUD-001H is an oral spray of sumatriptan to treat headache.

"Sumatriptan is one of the most widely used drugs for the treatment of in adults. SUD-001H is a first-in-class mint-flavoured oral spray formulation of sumatriptan (marketed in tablet form and in a nasal spray by under the brand name Imitrex)," it added.

Strides Pharma Science said the product will be filed with the (USFDA) and on approval is expected to be the first fast-acting oral spray of sumatriptan in the US market.

Strides said, the company will have a right of first refusal for additional territories including the European Union, and New Zealand, Canada, and

"Execution of Strides' generic product pipeline for the US is nearing completion and is expected to have over 150 abbreviated new drug application (ANDA) filings by 2021. The company is now focusing on developing a portfolio of complex and specialty products," the company said.

The company through in-house development and partnerships will build a portfolio of offering exclusivity for a sustainable period, it added.

Shares of Strides Pharma Science were trading 7.68 per cent higher at Rs 461.80 apiece on BSE.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Fri, November 09 2018. 12:00 IST